Category: Replacement Heart Valves
Mitralign reports the 1st-in-human use of its minimally invasive device to treat tricuspid valve regurgitation under a compassionate use allowance in Germany.
Mitralign said today that surgeons in Germany implanted its tricuspid valve repair device in its 1st patient, under a "compassionate use" allowance in Germany.
Researchers recommend quick surgery for patients with severe symptomatic aortic stenosis
NEW YORK (Reuters Health) - Patients with severe symptomatic aortic stenosis who need aortic valve replacement should have the surgery as soon as possible, new research suggests.
"Our research highlights the importance of treating aortic stenosis in a timely fashion. Delays lead to unnecessary risk and patients should ideally have an aortic valve replacement within a month of diagnosis," Dr. Chris Malaisrie of Northwestern University, Feinberg School of Medicine, in Chicago, Illinois, told Reuters Health by email.
Boston Scientific launches a U.S. clinical trial of its Lotus transcatheter aortic valve implant in high-and extreme-risk patients.
Edwards Lifesciences CEO Michael Mussallem discusses the company's recent FDA win for the Sapien replacement heart valve in this 2011 interview with MassDevice publisher Brian Johnson
Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.
Boston Scientific's Lotus replacement heart valve shows low leakage rates and no instances of moderate or severe leakage, a problem that plagued the earlier generation of transcatheter aortic valve implants.
Transcatheter aortic valve implants take center stage at the annual Transcatheter Cardiovascular Therapeutics conference with the latest data dumps from rivals Medtronic and Edwards Lifesciences.